BPC-157 + TB-500 + KPV + GHK-Cu (KLOW Blend)

Also known as: KLOW Healing Blend, Quad Peptide Stack, KLOW Blend

Evidence: Preclinical

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Vial blend of BPC-157, TB-500 (Ac-LKKTETQ), KPV and GHK-Cu, sold as 80 mg (10/10/10/50 mg); each component has animal or cell data, and no study has tested the four together.

Sold as an 80 mg vial holding 10 mg each of BPC-157, TB-500 and KPV plus 50 mg GHK-Cu, so GHK-Cu is over 60% of each dose. TB-500 is the acetylated fragment Ac-LKKTETQ, not full thymosin beta-4 (Esposito 2012). KPV is the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val); it reduced colitis in mice, mostly when given orally. BPC-157 and TB-500 have rodent tissue-repair data, and GHK-Cu raised collagen in cell and rat wound studies, with human data only for topical use. No human trial exists for KPV, TB-500 or the blend, and the one paired study of BPC-157 and TB-500 found no added benefit in rat tendon repair (Biçer 2026). FDA lists all four components (GHK-Cu for injection) on its compounding safety-risk page in the withdrawn-nomination table.

Benefits

Tendon and ligament repair (rodent, BPC-157); angiogenesis and wound repair (rodent and cell, TB-500 fragment); reduced colitis (mouse, KPV); collagen synthesis (cell and rat, GHK-Cu). No data for the blend

Dosing reference

Research dose: 500 to 1000 mcg of blend daily (about 60 to 125 mcg each of BPC-157, TB-500 and KPV and 310 to 625 mcg GHK-Cu at the 10/10/10/50 mg ratio): vendor/community range, no published human dose of the blend
Range: 500 to 1000 mcg, 1x daily
Reconstitution: 2 mL bacteriostatic water
Common vial sizes: 80 mg

Subcutaneous in community use. The loading-then-maintenance schedule has no published basis. The earlier text gave the dose as 0.5 to 1 mL, which at 80 mg in 2 mL would be 20 to 40 mg of blend, 20 to 80 times the numeric range; the numeric range is kept and the volume wording dropped. KPV animal work used oral drinking water, intraperitoneal 1 mg/kg in mice and topical 1 to 10 mg/mL; GHK-Cu human data are topical.

Mechanism

Proposed, from separate component studies; no study has measured an interaction among the four. BPC-157 activated VEGFR2-Akt-eNOS signalling in rat ischemic limbs. TB-500 carries the actin-binding motif of thymosin beta-4 linked to endothelial migration (Philp 2003). KPV entered intestinal epithelial and T cells through the PepT1 transporter and inhibited NF-kB and MAP kinase signalling at nanomolar levels (Dalmasso 2008); it also worked in MC1 receptor-deficient mice, so the effect is partly independent of MC1R (Kannengiesser 2008). GHK-Cu raised collagen synthesis in fibroblasts (Maquart 1988). Most KPV data used oral or colonic delivery; whether subcutaneous KPV reaches the gut mucosa has not been studied.

Evidence

Preclinical: animal or in vitro data only

Rat Achilles tendon repair (n=32): BPC-157 and TB-500 each improved histology, and the pair gave no added benefit over either alone; KPV and GHK-Cu were not tested (Biçer et al., 2026)
BPC-157 at 10 mcg or 10 ng/kg intraperitoneally restored transected rat Achilles tendon integrity and load to failure by day 14 (Staresinic et al., 2003)
Oral KPV in drinking water reduced DSS- and TNBS-induced colitis in mice, acting through PepT1 uptake and NF-kB inhibition (Dalmasso et al., 2008)
GHK-Cu raised collagen synthesis in fibroblast culture from 10^-12 M, peaking at 10^-9 M (Maquart et al., 1988)
Topical GHK-Cu gel improved diabetic foot ulcer closure versus vehicle in a multicenter evaluator-blinded RCT; this was topical, not injected (Mulder et al., 1994)
Human-trial status: no study has tested the blend as sold. No human trial of KPV or Ac-LKKTETQ has been published, BPC-157 has only uncontrolled pilot reports, and GHK-Cu human data are topical

References

Side effects

No human safety study of the blend has been published, and FDA states it has identified no human exposure data for KPV or the LKKTETQ fragment. Commonly reported by users (anecdotal): injection-site stinging, redness and lumps, attributed to GHK-Cu, plus transient fatigue. GHK-Cu is 50 of 80 mg and about 16% copper by mass; copper load is a theoretical concern in disorders of copper excretion such as Wilson's disease. Listed on FDA's 503A category 2 (safety concerns) page, withdrawn-nomination table, as of 2026-04-22, for BPC-157, TB-500, KPV and injectable GHK-Cu: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks.

Storage

Storage: Refrigerate 2-8°C (36-46°F)
Lyophilized: 2+ years at room temp, 3+ years refrigerated
Reconstituted: 28-30 days refrigerated

Pharmacology

Half-life: BPC-157 under 30 min (rat and dog). TB-500, KPV and GHK-Cu: not measured in any species. No human PK for any component
Bioavailability: BPC-157 intramuscular 14 to 19% (rat), 45 to 51% (dog). KPV active orally in mice via PepT1. TB-500, KPV and GHK-Cu by injection not measured